A share price of Summit Therapeutics Inc [SMMT] is currently trading at $20.16, up 1.56%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SMMT shares have gain 2.96% over the last week, with a monthly amount drifted -16.03%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on June 11, 2025, when Leerink Partners initiated its Underperform rating and assigned the stock a price target of $12. Previously, Citigroup upgraded its rating to Buy on March 26, 2025, and elevated its price target to $35. On March 21, 2025, Cantor Fitzgerald initiated with a Overweight rating. Evercore ISI started tracking the stock assigning a Outperform rating and suggested a price target of $30 on March 12, 2025. Goldman initiated its recommendation with a Buy and recommended $42 as its price target on February 28, 2025. Truist started tracking with a Buy rating for this stock on January 08, 2025, and assigned it a price target of $35. In a note dated December 11, 2024, Wells Fargo initiated an Overweight rating and provided a target price of $30 on this stock.
Summit Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $6.78 and $36.91. Currently, Wall Street analysts expect the stock to reach $38.25 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $20.16 at the most recent close of the market. An investor can expect a potential return of 89.73% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -0.7 and Total Capital is -0.48. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.72 points at the first support level, and at 19.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.54, and for the 2nd resistance point, it is at 20.91.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Summit Therapeutics Inc [NASDAQ:SMMT] is 10.63. As well, the Quick Ratio is 10.63, while the Cash Ratio is 6.06.
